deferasirox has been researched along with Colorectal Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Al-awar, R; Alizadeh, S; Aman, A; Attisano, L; Bao, RY; Chau, A; Christova, T; Gronda, M; Hogge, DE; Hurren, R; Isaac, M; Jitkova, Y; Joseph, B; Kasper, J; Miller, BW; Perusini, S; Schimmer, AD; Song, S; Subramaniam, R; Weir, SJ; Wrana, JL | 1 |
1 trial(s) available for deferasirox and Colorectal Neoplasms
Article | Year |
---|---|
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Colorectal Neoplasms; Deferasirox; Deferoxamine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydrazones; Iron; Iron Chelating Agents; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Wnt Proteins; Wnt Signaling Pathway | 2011 |